Complement Mediated Inflammation

Complement Mediated Inflammation Background

The complement system is a potent component of the innate immune response, promoting inflammation and orchestrating defense against pathogens. Complement activation is initiated by the pattern-recognition molecules complement component C1q, mannose-binding lectin (MBL) and ficolins (H-ficolin, L-ficolin, M-ficolin), which typically recognize antibody-antigen complexes or foreign polysaccharides. The associated proteases (C1r, C1s, MASP-1 and MASP-2) then activate the complement system. The serpin C1-inhibitor (C1-inh) blocks activity of all these complexes and has been successfully used in models of disease. Many structures of these components became available recently, including that of C1-inh, facilitating the structure-guided design of drugs targeting complement activation. Complement-mediated inflammation has been linked to ischemia-reperfusion injury, organ graft rejection and even neurodegeneration, so targeting this process has direct clinical implications.

Complement Mediated Inflammation Related Products

Other Complement Mediated Inflammation Related Products

Complement Mediated Inflammation References

1. Beinrohr L, et al. (2008). C1, MBL–MASPs and C1-inhibitor: novel approaches for targeting complement-mediated inflammation. Trends in molecular medicine, 14(12), 511-521.
2. Laudisi F, et al. (2013). Cutting edge: the NLRP3 inflammasome links complement-mediated inflammation and IL-1β release. The Journal of Immunology, 191(3), 1006-1010.